8-K: INBS Faces FDA 510(k) Resubmission for Drug Screening System

Intelligent Bio Solutions Inc. announced a delay in FDA 510(k) clearance for its fingerprint drug screening system, requiring a new submission.

Summary

• Intelligent Bio Solutions Inc. (INBS) provided an update on the FDA 510(k) clearance process for its Intelligent Fingerprinting Drug Screening System.
• The FDA requested new additional information, necessitating the resubmission of a new 510(k) notification.
• The FDA's requests were communicated in a letter dated September 12, 2025.
• INBS initially submitted its 510(k) premarket notification in December 2024.
• An initial Additional Information (AI) request with over 70 items was issued by the FDA in February 2025, to which INBS responded in August 2025.
• The Intelligent Fingerprinting Drug Screening System is a first-of-its-kind device with no comparable cleared or approved sweat-based product currently on the market.
• The company expects to provide an investor update within the next ten days outlining an updated timeline for FDA clearance.
• International business continues to grow, maintaining commercial progress globally outside the Forensic Use Only market.

Sentiment

Score: 4

Explanation: The delay in FDA clearance and requirement for resubmission is a significant setback, indicating a longer path to market. However, management's confidence, the 'constructive clarity' from the FDA, and continued international business growth provide some mitigating factors, preventing a lower score.

Positives

• FDA feedback provides constructive clarity on required additional information.
• Management expresses confidence in the technology's capabilities and commitment to the U.S. market.
• Progress in collecting additional data substantiates the product's strength.
• International business continues to grow, developing new partnerships and driving sales growth globally.

Negatives

• FDA requested new additional information, requiring a resubmission of the 510(k) notification.
• The clearance process for the Intelligent Fingerprinting Drug Screening System will be delayed.
• The device requires extensive supporting information due to being a first-of-its-kind sweat-based product.

Risks

• Ability to successfully develop and commercialize drug and diagnostic tests.
• Ability to realize commercial benefit from partnerships and collaborations.
• Ability to secure regulatory approvals, specifically FDA 510(k) clearance.
• Uncertainty of future events or outcomes related to regulatory processes.

Future Outlook

Intelligent Bio Solutions Inc. expects to provide an investor update within the next ten days to outline an updated timeline for FDA clearance. The company remains committed to bringing its innovative solution to the U.S. market and will work to respond to the FDA's additional questions to resubmit its 510(k) Notification as soon as possible. International business is expected to continue growing, developing new partnerships and driving sales growth while pursuing further international market penetration.

Management Comments

• "The FDAs feedback provides constructive clarity on the additional information it requires to advance our application."
• "We are confident in the capabilities of our technology, and we remain fully committed to bringing our innovative solution to the U.S. market."
• "We will work to respond to the FDAs additional questions to support validation of our device, in order to resubmit our 510(k) Notification as soon as possible."
• "The progress we have made so far in terms of additional data collected to substantiate the strength of our product throughout this process places us in a strong position as we work toward clearance."
• "Importantly, our international business continues to grow, enabling us to maintain commercial progress globally while pursuing U.S. clearance outside of the Forensic Use Only market."

Industry Context

The Intelligent Fingerprinting Drug Screening System is described as a first-of-its-kind device with no comparable cleared or approved sweat-based product currently on the market. This positions INBS as a potential innovator in the rapid, non-invasive drug testing sector, but also means it faces higher regulatory hurdles typical for breakthrough technologies without established precedents.

Stakeholder Impact

• Shareholders: Likely negative impact due to delayed market entry for a key product, creating uncertainty regarding future revenue streams from the U.S. market.
• Employees: Continued work required to address FDA feedback and resubmit the application.
• Customers (International): No direct negative impact; international business continues to grow.
• Potential U.S. Customers: Delayed access to the innovative drug screening system.

Next Steps

• Evaluate the FDA's questions in consultation with specialized FDA consultants.
• Work to respond to the FDA's additional questions to support validation of the device.
• Resubmit the 510(k) Notification as soon as possible.
• Provide an investor update within the next ten days outlining an updated timeline for FDA clearance.
• Continue to advance commercial activities outside the U.S., developing new partnerships and driving sales growth.

Key Dates

Recommendation

The requirement for a full 510(k) resubmission represents a material delay and increased uncertainty for Intelligent Bio Solutions' key product entry into the U.S. market. While management expresses confidence and international operations continue to perform, the regulatory setback introduces significant risk. A 'hold' recommendation is appropriate given the current uncertainty surrounding the revised timeline for FDA clearance, advising investors to await further clarity from the upcoming investor update before making new investment decisions.

Keywords

Intelligent Bio Solutions, INBS, FDA 510(k), Drug Screening System, Fingerprint Drug Test, Medical Technology, Regulatory Approval, Sweat Analysis, Diagnostic Tests, Biotechnology